Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shiba Wei Ou Qu Wan is a traditional Tibetan medicine manufactured by Xizang Ganlu Tibetan Medicine. It is an oral pill formulated with eighteen ingredients, including processed minerals (such as calomel or mercury sulfide) and various herbs like Terminalia chebula and musk. The medicine is primarily indicated for conditions associated with 'Chu-ser' (yellow fluid) imbalance in Tibetan medical theory, which manifests as inflammatory joint diseases like rheumatoid arthritis and gout, as well as various dermatological conditions including leprosy, scabies, and chronic eczema. It functions by clearing heat, detoxifying, and drying the 'yellow fluid' to alleviate pain and inflammation. It is an approved pharmaceutical product in China under the National Drug License Number Z54020074.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shiba Wei Ou Qu Wan.